Search
Anethole trithione
go.drugbank.com/drugs/DB13853Approvedappears to have a broad range of unique functions, from increasing salivary secretion to help treat xerostomia [A27165, A32618, A32620, A32621], to demonstrating an ability to inhibit carcinogenesis by
Moexipril
go.drugbank.com/drugs/DB00691ApprovedInvestigationalIt works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems.
Besilesomab
go.drugbank.com/drugs/DB13979ApprovedUtilised only as a diagnostic agent, besilesomab is currently approved by the EMEA for marketing and use in various European countries like Italy, France, Germany, Spain, Portugal, Norway, Sweden, the
Cinnarizine
go.drugbank.com/drugs/DB00568ApprovedInvestigationalFirst synthesized by Janssen Pharmaceuticals in 1955, cinnarizine is an anti-histaminic drug mainly used for the control of vestibular disorders and motion sickness.
Dacarbazine
go.drugbank.com/drugs/DB00851ApprovedInvestigationalAn antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.
Acetyl sulfisoxazole
go.drugbank.com/drugs/DB14033ApprovedVet approvedIt is often combined with erythromycin to treat acute otitis media caused by the bacteria, haemophilus influenzae [L2790].
alpha-Tocopherol acetate
go.drugbank.com/drugs/DB14003ApprovedAlpha-tocopherol is the primary form of vitamin E that is preferentially used by the human body to meet appropriate dietary requirements.
Collagenase clostridium histolyticum
go.drugbank.com/drugs/DB00048ApprovedInvestigationalCollagenase clostridium histolyticum is an enzyme produced by the bacterium Clostridium histolyticum. … [L14912] On July 6, 2020 a combination of injectable bacterial collagenases was approved by the FDA for the treatment of cellulite in adult women.
Dibotermin alfa
go.drugbank.com/drugs/DB11639ApprovedInvestigationalDibotermin alfa was approved by the EMA in 2002 as Inductos for implantation matrix. In 2004, it was approved by the FDA and is marketed as Infuse.
Padeliporfin
go.drugbank.com/drugs/DB15575ApprovedInvestigational[A244699] Padeliporfin was first approved by the European Commission on November 10, 2017, for the treatment of low-risk prostate cancer in adults meeting certain clinical criteria.[L39799]